Quinupristin dalfopristin indications and usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Quinupristin dalfopristin }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SYNERCID (QUINUPRISTIN AND DA...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications And Usage== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SYNERCID (QUINUPRISTIN AND DALFOPRISTIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28f698df-b584-4455-2e94-6efc41313960 | publisher = | date = | accessdate = }}</ref> | Synercid is indicated in adults for the treatment of the following infections when caused by susceptible strains of the designated microorganisms. | ||
Complicated skin and skin structure infections caused by [[Staphylococcus aureus ]](methicillin susceptible) or [[Streptococcus pyogenes]]. (See Clinical Studies.) <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SYNERCID (QUINUPRISTIN AND DALFOPRISTIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=28f698df-b584-4455-2e94-6efc41313960 | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 05:39, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
Synercid is indicated in adults for the treatment of the following infections when caused by susceptible strains of the designated microorganisms.
Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin susceptible) or Streptococcus pyogenes. (See Clinical Studies.) [1]
References
Adapted from the FDA Package Insert.